The most upregulated pathways in T-LGLL included IFNγ-response (upregulated in 12/16 subsets vs. other cancers, 16/17 vs. healthy, 9/15 vs other blood cancers), IFNα-response (9/16 vs. other cancers, 15/17 vs. healthy, 8/15 vs other blood cancers), and NFκB (11/16 vs. other cancers, 0/17 vs. healthy, 4/15 vs other blood cancers) pathways (Fig. 5c, Supplementary Fig. 14c, d). The gene discussed is NFKB1; the disease is hematopoietic and lymphoid system neoplasm.